4.6 Article

S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways

期刊

CELL BIOLOGY AND TOXICOLOGY
卷 37, 期 4, 页码 555-571

出版社

SPRINGER
DOI: 10.1007/s10565-020-09574-w

关键词

Pancreatic cancer; Metastasis; AKT; ERK1/2

资金

  1. National Natural Science Foundation of China [81902803, 82072739]
  2. Zhejiang Provincial Natural Science Foundation [LY21H160057]
  3. Science and Technology Bureau of Wenzhou [Y20190069]
  4. Innovative and Entrepreneurial Team [(2018)2015]
  5. Science and Technology Grant [BE2019758]
  6. Natural Science Foundation of Jiangsu Province [BK20190657]
  7. Southeast UniversityNanjing Medical University Cooperative Research Project [2242018K3DN33]
  8. Funding of Peak Training Program for ScientificResearch of Yijishan Hospital, Wannan Medical College [GF2019G19]
  9. China Postdoctoral Science Foundation [2019M651897]
  10. Science and Technology Development Fund of Nanjing Medical University [NMUB2018015]
  11. Overseas Young Talents Project of China

向作者/读者索取更多资源

The S100A16 gene, located on chromosome 1q21, is significantly upregulated in pancreatic ductal adenocarcinoma (PDAC) samples. It promotes PDAC progression through FGF19-mediated AKT and ERK1/2 signaling, indicating S100A16 as a promising therapeutic target for PDAC.
The S100 protein family genes play a crucial role in multiple stages of tumorigenesis and progression. Most of S100 genes are located at chromosome locus 1q21, which is a region frequently rearranged in cancers. Here, we examined the expression of the S100 family genes in paired pancreatic ductal adenocarcinoma (PDAC) samples and further validated the expression of S100A16 by immunohistochemistry staining. We found that S100A16 is significantly upregulated in clinical PDAC samples. However, its roles in PDAC are still unclear. We next demonstrated that S100A16 promotes PDAC cell proliferation, migration, invasion, and metastasis both in vitro and in vivo. Knockdown of S100A16 induces PDAC cell cycle arrest in the G2/M phase and apoptosis. Furthermore, we also demonstrated that S100A16 promotes PDAC cell proliferation, migration, and invasion via AKT and ERK1/2 signaling in a fibroblast growth factor 19 (FGF19)-dependent manner. Taken together, our results reveal that S100A16 is overexpressed in PDAC and promotes PDAC progression through FGF19-mediated AKT and ERK1/2 signaling, suggesting that S100A16 may be a promising therapeutic target for PDAC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据